4CPS-106 Safety of adjuvant trastuzumab emtansina for residual invasive HER2-positive early breast cancer | European Journal of Hospital Pharmacy

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Section 4: Clinical pharmacy services

4CPS-106 Safety of adjuvant trastuzumab emtansina for residual invasive HER2-positive early breast cancer

Free

Online download statistics by month:

Online download statistics by month: March 2022 to October 2024

	Abstract	Full	Pdf
Mar 2022	32	0	1
Apr 2022	50	0	6
May 2022	9	0	3
Jun 2022	37	0	7
Jul 2022	37	0	3
Aug 2022	17	0	4
Sep 2022	16	0	6
Oct 2022	19	0	6
Nov 2022	16	0	2
Dec 2022	15	0	3
Jan 2023	16	0	0
Feb 2023	12	0	2
Mar 2023	11	0	2
Apr 2023	2	0	0
May 2023	4	0	1
Jun 2023	8	0	3
Jul 2023	10	0	2
Aug 2023	6	0	1
Sep 2023	12	0	3
Oct 2023	6	0	1
Nov 2023	13	0	2
Dec 2023	10	0	1
Jan 2024	4	0	1
Feb 2024	16	0	5
Mar 2024	12	0	1
Apr 2024	12	0	2
May 2024	10	0	2
Jun 2024	11	0	0
Jul 2024	6	0	6
Aug 2024	5	0	2
Sep 2024	15	0	1
Oct 2024	3	0	1
Total	452	0	80